People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

The American Diabetes Association has recognized Bonner General Health through the organization's Education Recognition Program. The diabetes self-management education and support service was ...

Aspirus Iron River, Aspirus Ironwood and Aspirus Keweenaw Hospitals were recently awarded the American Diabetes Association Education Recognition Certificate for quality diabetes management education ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

In addition to meeting the primary endpoint of superior A1C reduction, the once-daily oral pill reduced weight by an average ...

Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...

India has a high prediabetes prevalence (15.3%), nearly equal in urban (15.4%) and rural (15.2%) areas. (1) In India, ...

That three-pronged attack helped patients lose an average of about 24% of their body weight at 48 weeks in a phase 2 trial presented at the American Diabetes Association (ADA) congress.